Neuropathology and emerging biomarkers in corticobasal syndrome

S Koga, KA Josephs, I Aiba, M Yoshida… - Journal of Neurology …, 2022 - jnnp.bmj.com
Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive
asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and …

Clinical spectrum of tauopathies

N Olfati, A Shoeibi, I Litvan - Frontiers in Neurology, 2022 - frontiersin.org
Tauopathies are both clinical and pathological heterogeneous disorders characterized by
neuronal and/or glial accumulation of misfolded tau protein. It is now well understood that …

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains

ML Malarte, PG Gillberg, A Kumar, N Bogdanovic… - Molecular …, 2023 - nature.com
Recent mechanistic and structural studies have challenged the classical tauopathy
classification approach and revealed the complexity and heterogeneity of tau pathology in …

Tau PET imaging in neurodegenerative disorders

C Groot, S Villeneuve, R Smith… - Journal of Nuclear …, 2022 - jnm.snmjournals.org
The advent of PET ligands that bind tau pathology has enabled the quantification and
visualization of tau pathology in aging and in Alzheimer disease (AD). There is strong …

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies

A Lindberg, E Murrell, J Tong, NS Mason… - Nature …, 2024 - nature.com
Positron emission tomography (PET) imaging of tau aggregation in Alzheimer's disease
(AD) is hel** to map and quantify the in vivo progression of AD pathology. To date, no …

Overview of tau PET molecular imaging

GC Petersen, M Roytman, GC Chiang… - Current opinion in …, 2022 - journals.lww.com
Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe Get new issue
alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation Subscribe …

Amyloid and tau positron emission tomography imaging in Alzheimer's disease and other tauopathies

C Maschio, R Ni - Frontiers in aging neuroscience, 2022 - frontiersin.org
The detection and staging of Alzheimer's disease (AD) using non-invasive imaging
biomarkers is of substantial clinical importance. Positron emission tomography (PET) …

Magnetic resonance imaging measures to track atrophy progression in progressive supranuclear palsy in clinical trials

A Quattrone, N Franzmeier, HJ Huppertz… - Movement …, 2024 - Wiley Online Library
Background Several magnetic resonance imaging (MRI) measures have been suggested as
progression biomarkers in progressive supranuclear palsy (PSP), and some PSP staging …

Amyloid-β prediction machine learning model using source-based morphometry across neurocognitive disorders

Y Momota, S Bun, J Hirano, K Kamiya, R Ueda… - Scientific reports, 2024 - nature.com
Previous studies have developed and explored magnetic resonance imaging (MRI)-based
machine learning models for predicting Alzheimer's disease (AD). However, limited research …

A Machine Learning–Based Approach to Discrimination of Tauopathies Using [18F]PM‐PBB3 PET Images

H Endo, K Tagai, M Ono, Y Ikoma, A Oyama… - Movement …, 2022 - Wiley Online Library
Background We recently developed a positron emission tomography (PET) probe,[18F] PM‐
PBB3, to detect tau lesions in diverse tauopathies, including mixed three‐repeat and four …